Not satisfied with simply changing personnel, Japanese drugmaker Astellas has announced a new management structure, effective ...

Astellas is preparing a significant shake-up of its top-tier roles, including transforming its chief medical officer into a new R&D position and ushering out its current chief scientific officer ...

Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to reach the finish line. Now, following a review of its pipeline ...

Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker has made diversification a key part of its growth strategy. Newer products in its drug lineup include a ...

The new Astellas agreement comes a few months after the FORTIS study of AT845 was placed under a clinical hold by the FDA after a serious adverse event – peripheral sensory neuropathy – was ...

TOKYO, Feb. 4, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective ...

Astellas is ready to launch its first digital ... Ultimately, the aim is to prevent acute decompensation events and re-hospitalisations. Digitiva (formerly known as Z1608) has been listed by ...

Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) ...